Dr. Regina Barragan-Carrillo from City of Hope Comprehensive Cancer Center in conversation with Dr. Elizabeth Plimack from Fox Chase Cancer Center
Drs. Barragan-Carillo & Plimack delved into the latest approaches for treating patients with localized high-risk kidney cancer following nephrectomy, including the use of adjuvant pembrolizumab and exciting clinical trials involving the V940 vaccine.
Dr. Plimack shared her strategies for managing patients who relapsed after adjuvant immunotherapy, emphasizing the importance of treating them as de novo first-line patients. The discussion also covered the integration of cytoreductive nephrectomy in metastatic disease, particularly in light of findings from the CARMENA trial.
As they explored first-line systemic therapy options, Dr. Plimack highlighted the ongoing debate between immunotherapy (IO) and TKI and discussed factors that influence regimen selection. She also provided insights into her approach for sequencing treatments after progression on initial therapies, including the use of Cabozantinib and the potential of re-challenging with immunotherapy.